Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 69917-80-2 ] Purity: 98% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 69917-80-2 ]

CAS No. :	69917-80-2
Formula :	C₈H₁₁NO₂
M.W :	153.18
SMILES Code :	O=C(OC)CCC1=CC=CN1
MDL No. :	MFCD09841003
InChI Key :	UBOXXEGSGUIRAJ-UHFFFAOYSA-N
Pubchem ID :	14668764

Safety of [ 69917-80-2 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Computational Chemistry of [ 69917-80-2 ] Show Less

Physicochemical Properties

Num. heavy atoms	11
Num. arom. heavy atoms	5
Fraction Csp3	0.38
Num. rotatable bonds	4
Num. H-bond acceptors	2.0
Num. H-bond donors	1.0
Molar Refractivity	41.46
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	42.09 ?2

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	1.77
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	0.83
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	1.12
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	0.44
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	1.88
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	1.21

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-1.38
Solubility	6.31 mg/ml ; 0.0412 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Very soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-1.3
Solubility	7.74 mg/ml ; 0.0505 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Very soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-2.48
Solubility	0.511 mg/ml ; 0.00333 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	No
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-6.65 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	1.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	0.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	1.51

Application In Synthesis of [ 69917-80-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 69917-80-2 ]

[ 69917-80-2 ] Synthesis Path-Downstream 1~32

1
[ 186581-53-3 ]
[ 408309-29-5 ]
[ 69917-80-2 ]

References: [1]Hoppe-Seyler's Zeitschrift fur Physiologische Chemie,1952,vol. 289,p. 229,231.

2
7-Azido-6-methoxy-4-oxo-heptanoic acid methyl ester [ No CAS ]
[ 69917-80-2 ]

References: [1]Angewandte Chemie,1990,vol. 102,p. 828 - 830.

3
[ 69917-80-2 ]
[ 55490-38-5 ]

References: [1]Bioorganic and Medicinal Chemistry Letters,1996,vol. 6,p. 1541 - 1542.

4
[ 49616-56-0 ]
[ 69917-80-2 ]

Yield	Reaction Conditions	Operation in experiment
82%	With palladium on activated charcoal; hydrogen; In methanol;	(0071) The BODIPY acid 11, used for preparing the azole fluorescent probes, was synthesized depicted in Scheme 2, following the procedure disclosed in Vanessa Saura et al. (2017).
5 g	With palladium 10% on activated carbon; hydrogen; In methanol; at 18℃; under 2585.81 Torr; for 10h;Inert atmosphere;	[0278] To a solution of compound 15.6 (8.60 g, 56.89 mmol, 1.00 eq) m MeOH (100.00 mL) was added Pd-C (10%, 0.9 g) under N2. The suspension was degassed under vacuum and purged with H2 several times. The mixture was stirred under H2 (50psi) at 18C for 10 hours. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (S1O2, petroleum ether/ethyl acetate=5: l) to afford compound 15.5 (5.00 g, 32.64 mmol, 57.37% yield) as a colorless oil.

References: [1]Bioorganic and Medicinal Chemistry Letters,1996,vol. 6,p. 1541 - 1542.
[2]Organic and Biomolecular Chemistry,2017,vol. 15,p. 3013 - 3024.
[3]Patent: US2020/72711,2020,A1 .Location in patent: Paragraph 0071.
[4]Patent: WO2018/53353,2018,A1 .Location in patent: Paragraph 0278; 0357.

Yield	Reaction Conditions	Operation in experiment
5.10 g (82%)		The reaction mixture was filtered through a diatomaceous earth pad and the filtrate was concentrated under vacuum to give 5.10 g (82%) of compound 31 as a pale yellow oil.

6
[ 91642-12-5 ]
[ 69917-80-2 ]

References: [1]Hoppe-Seyler's Zeitschrift fur Physiologische Chemie,1952,vol. 289,p. 229,231.

7
[ 100371-16-2 ]
[ 69917-80-2 ]

References: [1]Hoppe-Seyler's Zeitschrift fur Physiologische Chemie,1952,vol. 289,p. 229,231.

8
[ 69917-80-2 ]
3-(5-formyl-1H-pyrrol-2-yl)propionic acid methyl ester [ No CAS ]
[ 10087-64-6 ]

Yield	Reaction Conditions	Operation in experiment
		The 2,2'-bipyrrole is prepared as described in Rappaport et al., J. AM. CHEM. SOC., 84, 2178 (1962). The 2-(2-methoxycarbonylethyl)-5-formylpyrrole is prepared from 2-(2-methoxycarbonylethyl)pyrrole by the Vilsmeier-Haack formylation according to ORG. SYNTH. COLL. Vol. IV, p 831.

References: [1]Patent: US5274113,1993,A .

9
[ 1017802-42-4 ]
[ 69917-80-2 ]

References: [1]Synthesis,2008,p. 237 - 244.

10
[ 1190426-25-5 ]
[ 69917-80-2 ]

References: [1]Angewandte Chemie - International Edition,2009,vol. 48,p. 6511 - 6515.
Angewandte Chemie,2009,vol. 121,p. 6633 - 6637.
[2]Chemistry - A European Journal,2010,vol. 16,p. 9676 - 9685.

11
5-(4-methoxyphenyl)-1H-pyrrole-2-carbaldehyde [ No CAS ]
[ 69917-80-2 ]
methyl 3-[4,4-difluoro-5-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene-3-yl]propionate [ No CAS ]

References: [1]European Journal of Organic Chemistry,2010,p. 3611 - 3620.

12
[ 2199-58-8 ]
[ 69917-80-2 ]
methyl 3-(5,5-difluoro-7,9-dimethyl-5H-4λ⁴,5λ⁴-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-yl)propanoate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
50.05%		[0279] To a mixture of compound 15.5 (3.00 g, 19.58 mmol, 1 .00 eq) and compound 15.4 (2.65 g, 21.54 mmol, 1.10 eq) in DCM (60.00 mL) was added PGCL (3.30 g, 21.54 mmol, 2.00 iriL, 1.10 eq) in one portion at 18C under N2. The mixture was stirred at 18 C for 10 hours, followed by addition of BF3 Et20 (1 1.12 g, 78.32 mmol, 9.67 mL, 4.00 eq) and DIEA (10.63 g, 82.24 mmol, 14.36 mL, 4.20 eq) dropwise at 18 C. The mixture was stirred at 18 C for 10 hours. The reaction mixture was filtered, diluted with H20 (50 mL), and extracted with DCM (3 x 50 mL). The combined organic layers were washed with brine (100 mL), dried over Na2S04, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (S1O2, petroleum ether/ethyl acetate=l :4) to afford compound 15.3 (3.00 g, 9.80 mmol, 50.05% yield) as a red solid.

References: [1]European Journal of Organic Chemistry,2010,p. 3611 - 3620.
[2]Patent: WO2018/53353,2018,A1 .Location in patent: Paragraph 0279; 0358.

13
[ 32585-91-4 ]
[ 69917-80-2 ]

Yield	Reaction Conditions	Operation in experiment
100%	With palladium on activated charcoal; hydrogen; In methanol; at 20℃; for 16h;	A solution of (E)-methyl 3-(1H-pyrrol-2-yl)acrylate 3 (3.15g, 21.1mmol) in MeOH (160mL) was placed under at atmosphere of argon. Pd/C (246mg, 10%) was added, followed by replacement of the argon with a hydrogen atmosphere. The reaction was then stirred at rt until completion as indicated by TLC analysis (16h). The crude mixture was filtered over a bed of Celite, and the Celite plug was eluted a further aliquot of MeOH (50mL). The combined MeOH washes were then concentrated in vacuo to afford ester 4 (3.13g, 100%) as a pale yellow oil, which required no further purification. The NMR data obtained for ester 4 is in accordance with the literature. 1H NMR (CDCl3, 400MHz) delta: 8.53 (1H, br s), 6.69-6.68 (1H, m), 6.13-6.10 (1H, m), 5.94-5.93 (1H, m), 3.71 (3H, s), 2.93 (2H, t, J=6.6Hz), 2.66 (2H, t, J=6.6Hz). 13C NMR (CDCl3, 100MHz) delta: 174.5, 130.9, 116.8, 108.0, 105.5, 51.8, 34.4, 22.5.

References: [1]Tetrahedron,2013,vol. 69,p. 8527 - 8533.
[2]ACS Chemical Neuroscience,2019,vol. 10,p. 1445 - 1451.
[3]Chemistry - A European Journal,2018,vol. 24,p. 4957 - 4966.
[4]European Journal of Organic Chemistry,2010,p. 3611 - 3620.
[5]Journal of the American Chemical Society,2017,vol. 139,p. 15801 - 15811.

14
[ 69917-80-2 ]
[ 1313876-81-1 ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2011,vol. 21,p. 3546 - 3549.

15
[ 69917-80-2 ]
C₂₇H₃₃N₃O₄ [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2011,vol. 21,p. 3546 - 3549.

16
[ 69917-80-2 ]
[ 120-21-8 ]
C₂₇H₃₅N₃O₄ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With trifluoroacetic acid; In dichloromethane; at 20℃; for 24h;Inert atmosphere;	Methyl 3-(1H-pyrrol-2-yl)propanoate 2b (250 mg, 1.6 mmol) and 4-diethylamino-benzaldehyde 3b (145 mg, 0.8 mmol) were dissolved in 150 mL dry CH2Cl2 (argon was bubbled through CH2Cl2 for 30 min) under argon atmosphere. One drop of TFA was added and the reaction mixture was stirred at room temperature for 24 h under argon. p-Chloranil (202 mg, 0.8 mmol) was added and stirring was continued for 30 min under argon. Then, triethylamine (2.0 mL) and BF3*OEt2 (2.0 mL) were added, and the reaction mixture was stirred at room temperature overnight under argon. The reaction mixture was washed with H2O (40 mL), brine (40 mL), dried over Na2SO4, filtered, and evaporated. The crude mixture was purified by column chromatography on SiO2 (Hexane: EtOAc = 6:1 ~ 3:1) to afford 4d (222 mg, 0.43 mmol, 53% yield) as a red solid.

References: [1]Bioorganic and Medicinal Chemistry Letters,2011,vol. 21,p. 3546 - 3549.

17
[ 69917-80-2 ]
[ 1451009-75-8 ]